Background: Incidence of IPMN-Ca is increasing and due to lack of large prospective trials to evaluate optimal management of IPMN-Ca following resection, benefit of Adj is unknown. Methods: Retrospective review of patients (pts) who underwent pancreatic resection for invasive cancer from 2004 to 2012 at a single institution. Univariate and multivariate Cox regression models were used to determine association between different characteristics and survival. Results: From a total of 225 pancreatic resections (IPMN-Ca = 39, PDAC = 186), data regarding Adj was available in 179 pts (IPMN-Ca = 30, PDAC = 149). As shown in the Table, IPMN-Ca pts were less likely to receive Adj than PDAC (53% vs. 85% p = <0.001). There was no significant difference in tumor stage (stg) (early T vs advanced T) and Nodal stg (N0 vs. N1) distribution between pts who received Adj with IPMN-Ca or PDAC. Univariable survival analysis (SA): In PDAC, Adj improved overall survival (OS) (Hazard ratio [HR]: 0.46, 95% CI 0.28, 0.77), but there was no improvement in OS in IPMN-Ca pts with Adj (HR: 1.6, 95% CI 0.56, 4.64). Multivariable SA adjusting for age, Adj, resection margin, T, N stg: For PDACs, Adj was singularly associated with improved OS (HR 0.50, 95% CI 0.30, 0.82). In contrast, SA for IPMN-Ca did not reveal any significant contributing variable. For all pancreatic cancers, multivariable SA adjusting for IPMN-Ca vs. PDAC, age, Adj, resection margin, T, N stg revealed that a diagnosis of IPMN-Ca (HR: 0.52, 95% CI 0.30, 0.91) and a negative resection margin (HR: 0.65, 95% CI 0.43, 0.96) were significantly associated with better OS. Conclusions: Post resection, although pts with IPMN-Ca have better OS than PDACs, Adj fails to influence OS in IPMN-Ca pts. Larger studies are needed to confirm these findings.